Alexis Paquin

Quebec, QC G8Z4M3, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Exploring the Synthesis, Anti-Inflammatory and Anti-Tumor Potential of 4-Maleimidylphenyl-Hydrazide Derivatives.

Exploring the Synthesis, Anti-Inflammatory and Anti-Tumor Potential of 4-Maleimidylphenyl-Hydrazide Derivatives.

Journal: Molecules (Basel, Switzerland)

Published: July 29, 2025

Inhibitory Impact of the Amino Benzoic Derivative DAB-2-28 on the Process of Epithelial-Mesenchymal Transition in Human Breast Cancer Cells.

Inhibitory Impact of the Amino Benzoic Derivative DAB-2-28 on the Process of Epithelial-Mesenchymal Transition in Human Breast Cancer Cells.

Journal: Molecules (Basel, Switzerland)

Published: July 02, 2025

Synthesis, Characterization, and Biological Evaluation of N-Methyl Derivatives of Norbelladine.

Synthesis, Characterization, and Biological Evaluation of N-Methyl Derivatives of Norbelladine.

Journal: Molecules (Basel, Switzerland)

Published: August 29, 2024

Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells.

Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells.

Journal: Anti-cancer drugs

Published: June 20, 2024

Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups.

Synthesis and anticancer properties of a hybrid molecule with the testosterone and estradiol head-groups.

Journal: Steroids

Published: May 17, 2024

Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.

Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.

Journal: ACS medicinal chemistry letters

Published: September 06, 2023

Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.

Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings.

Journal: Bioorganic & medicinal chemistry letters

Published: August 04, 2023

Investigating a new C2-symmetric testosterone dimer and its dihydrotestosterone analog: Synthesis, antiproliferative activity on prostate cancer cell lines and interaction with CYP3A4.

Investigating a new C2-symmetric testosterone dimer and its dihydrotestosterone analog: Synthesis, antiproliferative activity on prostate cancer cell lines and interaction with CYP3A4.

Journal: European journal of medicinal chemistry

Published: January 27, 2023

Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.

Innovative C2-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4.

Journal: European journal of medicinal chemistry

Published: March 26, 2021

Recent Advances in the Use of the Dimerization Strategy as a Means to Increase the Biological Potential of Natural or Synthetic Molecules.

Recent Advances in the Use of the Dimerization Strategy as a Means to Increase the Biological Potential of Natural or Synthetic Molecules.

Journal: Molecules (Basel, Switzerland)

Published: March 16, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026